TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04482569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW4107
Description: Single or multiple dose ascending study for XNW4107 alone or multiple dose study of XNW4107 in combination with imipenem/cilastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW4107
Description: Single or multiple dose ascending study for XNW4107 alone or multiple dose study of XNW4107 in combination with imipenem/cilastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW4107
Description: Single or multiple dose ascending study for XNW4107 alone or multiple dose study of XNW4107 in combination with imipenem/cilastatin
Study: NCT01275170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem + Cilastatin
Description: 250 mg IV over 30 minutes as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem + Cilastatin
Description: 250 mg IV over 30 minutes as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem + Cilastatin
Description: 250 mg IV over 30 minutes as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem + Cilastatin
Description: 250 mg IV over 30 minutes as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem + Cilastatin
Description: 250 mg IV over 30 minutes as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem + Cilastatin
Description: 250 mg IV over 30 minutes as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem + Cilastatin
Description: 250 mg IV over 30 minutes as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine caplet, single 200 mg dose, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine caplet, single 200 mg dose, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine caplet, single 200 mg dose, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine caplet, single 200 mg dose, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam hcl syrup single 2.0 mg dose by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam hcl syrup single 2.0 mg dose by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam hcl syrup single 2.0 mg dose by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam hcl syrup single 2.0 mg dose by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole tablets, single 40 mg dose (as two 20 mg tablets), orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole tablets, single 40 mg dose (as two 20 mg tablets), orally
Study: NCT04873947

Intervention type: DEVICE
Intervention: Pulse Oximeter
Description: The investigational device will be placed on the finger of the left or right hand per the instructions for use. Simultaneous data collection will be set up for the system under test and control oximeter.
Study: NCT01275170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole tablets, single 40 mg dose (as two 20 mg tablets), orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole tablets, single 40 mg dose (as two 20 mg tablets), orally
Study: NCT02866305

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VATS bullectomy and mechanical pleuradesis.
Description: Thoracoscopic bullectomy is performed on all visible bullae, alternatively is no visible bullae, the apex is resected. Then mechanical pleuradesis is performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VATS bullectomy and mechanical pleuradesis.
Description: Thoracoscopic bullectomy is performed on all visible bullae, alternatively is no visible bullae, the apex is resected. Then mechanical pleuradesis is performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest tube insertion
Description: Conventional chest tube insertion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest tube insertion
Description: Conventional chest tube insertion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest tube insertion
Description: Conventional chest tube insertion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest tube insertion
Description: Conventional chest tube insertion.
Study: NCT02866695

Intervention type: DRUG
Group type: OTHER
Intervention: ingenol mebutate gel 0.015%
Description: ingenol mebutate gel 0.015% to be applied on treatment area
Study: NCT02866305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural
Description: All surgical participants received an epidural prior to the procedure.The epidural was removed simultaneous with the the chest tube.
Study: NCT02399410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perioperative chemotherapy plus bevacizumab
Description: preoperative and postoperative combination chemotherapy with bevacizumab

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cytoreductive surgery
Description: complete or nearly complete removal of synchronous or metachronous peritoneal carcinomatosis from CRC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraperitoneal Oxaliplatin
Description: Pump-driven intraperitoneal administration of oxaliplatin
Study: NCT03520582

Intervention type: DEVICE
Intervention: Tube placement
Description: Placement of enteral feeding tubes

Intervention type: DEVICE
Intervention: Tube placement
Description: Placement of enteral feeding tubes
Study: NCT03525769

Intervention type: DIAGNOSTIC_TEST
Intervention: FibroTouch
Description: FibroTouch is a non-invasive image-guided integrated detection system, providing an integrated detection and comprehensive evaluation program for hepatic fibrosis and hepatic steatosis.~The FibroTouch is a completely non-invasive liver testing device that can obtain the following results: 1. Liver Fibrosis: quantitative results of hepatic fibrosis; 2. Fatness: quantitative result of hepatic steatosis; 3. Liver tissue morphology: detected by ultrasound imaging.
Study: NCT00696891

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine
Description: 3-dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: 3-dose intramuscular injection
Study: NCT02866305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural
Description: All surgical participants received an epidural prior to the procedure.The epidural was removed simultaneous with the the chest tube.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-resolution Computer Tomography
Description: All participants included in this study had a HRCT performed.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-resolution Computer Tomography
Description: All participants included in this study had a HRCT performed.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-resolution Computer Tomography
Description: All participants included in this study had a HRCT performed.
Study: NCT00345969

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal Testosterone gel (1%)
Description: Transdermal testosterone replacement therapy with Androgel(TM). Daily application of gel at 5 mg, 7.5 gm, or 10 gm for six months. Target serum total testosterone level between 500-900 ng/dl.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Supervised exercise training
Description: Supervised exercise training performed on site at academic medical center exercise facility. Exercise training consisted of 2 months of flexibility, balance, treadmill walking, and physical therapy-type exercises, followed by 4 months of progressive resistance training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised exercise training
Description: Supervised exercise training performed on site at academic medical center exercise facility. Exercise training consisted of 2 months of flexibility, balance, treadmill walking, and physical therapy-type exercises, followed by 4 months of progressive resistance training.
Study: NCT00991146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: canakinumab
Description: canakinumab
Study: NCT00329758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin
Description: 20 mg oral, during 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02866305

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-resolution Computer Tomography
Description: All participants included in this study had a HRCT performed.
Study: NCT01294709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telcagepant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telcagepant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to telcagepant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to telcagepant
Study: NCT03693235

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bending angle of a lightwand
Description: For tracheal intubation, investigators will bend the tracheal tube combined a lightwand by assigned angles (70, 80, or 90 degrees) for each patient. Next a practitioner will perform tracheal intubation with the bent tube.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bending angle of a lightwand
Description: For tracheal intubation, investigators will bend the tracheal tube combined a lightwand by assigned angles (70, 80, or 90 degrees) for each patient. Next a practitioner will perform tracheal intubation with the bent tube.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bending angle of a lightwand
Description: For tracheal intubation, investigators will bend the tracheal tube combined a lightwand by assigned angles (70, 80, or 90 degrees) for each patient. Next a practitioner will perform tracheal intubation with the bent tube.
Study: NCT03572049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUBA itraconazole
Description: SUBA itraconazole study drug will consist of two 65 mg capsules to be taken three times a day with food for days 1-3 of study. For days 4-180 of study, two 65mg capsules will be taken twice daily with food.
Study: NCT04290364

Intervention type: OTHER
Intervention: Palliative care
Description: The patients in the prospective part of the study are seen on home-visits and offered standard palliative care within three weeks of diagnosis.
Study: NCT03572049

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional itraconazole
Description: Conventional itraconazole comparator drug will consist of two 100 mg capsules to be taken three times a day with food for days 1-3 of study. For days 4-180 of study, two 100 mg capsules will be taken twice daily with food.
Study: NCT04189536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS Intervention
Description: Delivery of text messages will use the Rip Road Mobile platform.
Study: NCT04054011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic Acid
Description: Deoxycholic acid (Kybella) 10 mg/ mL subcutaneous
Study: NCT00648739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samalizumab
Description: Samalizumab is a humanized anti-CD200 monoclonal antibody.
Study: NCT03125239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Merestinib
Description: Oral, once a day, Merestinib Only- Lead in period on week. The followed by cycles on combination therapy with Merestinib and LY2874455 (28 days long)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2874455
Description: This will be followed by cycles of combination therapy with merestinib and LY2874455. Each of these cycles are 28 days long. • LY2874455 will be taken by mouth twice a day. You may take LY2874455 twice daily for 14 days, 21 days, or 28 days each cycle depending on the dose level you are assigned.
Study: NCT02387723

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic adipose derived stem cells (CSCC_ASC)
Description: Culture expanded allogeneic adipose derive stem cells (CSCC_ASC)
Study: NCT03390010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol + syntocinon and using extra uterotonic drugs when needed ; methergine
Description: medical prophylaxis against postpartum atony and postpartum hemorage by giving misoprostol plus syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntocinon and using extra uterotonic drugs when needed ; methergine carboprost
Description: medical prophylaxis against postpartum atony and postpartum hemorage by giving syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost
Study: NCT02788955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary counselling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary counselling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Protein

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Protein
Study: NCT00572910

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo (PBO)
Description: Group 6: Placebo (PBO / PBO / PBO)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V710 Comparator: Placebo (PBO)
Description: Group 5A: V710 (90 mcg / 90 mcg / 90 mcg) with MAA~Group 5B: V710 (90 mcg / 90 mcg / PBO) with MAA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V710 Comparator: Placebo (PBO)
Description: Group 4A: V710 (60 mcg / PBO / 60 mcg) with MAA~Group 4B: V710 (60 mcg / PBO / PBO) with MAA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V710 Comparator: Placebo (PBO)
Description: Group 3A: V710 (60 mcg / 60 mcg / 60 mcg) with MAA~Group 3B: V710 (60 mcg / 60 mcg / PBO) with MAA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V710 Comparator: Placebo (PBO)
Description: Group 2A: V710 (60 mcg / PBO / 60 mcg) without MAA~Group 2B: V710 (60 mcg / PBO / PBO) without MAA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V710 Comparator: Placebo (PBO)
Description: Group 1A: V710 (60 mcg / 60 mcg / 60 mcg) without MAA~Group 1B: V710 (60 mcg / 60 mcg / PBO) without MAA
Study: NCT02173132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetyl-L-carnitine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03099161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: preladenant
Description: Administered as an oral capsule BID on Days 1 through 21 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: preladenant
Description: Administered as an oral capsule BID on Days 1 through 21 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: preladenant
Description: Administered as an oral capsule BID on Days 1 through 21 of each 21-day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Administered as IV infusion on Day 1 of each 21-day cycle
Study: NCT01654211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: single iv infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: single iv infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: single iv infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: single iv infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: danoprevir
Description: single oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single iv infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: oral doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ritonavir
Description: oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: oral doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir
Description: oral doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir
Description: oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: oral doses
Study: NCT04681001

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasal spray
Description: application of nasal spray into nostrils and mouth

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: nasal spray
Description: application of nasal spray into nostrils and mouth
Study: NCT01412307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 10, 15, 20 or 25 mg orally per cohort day 1-28 in a 28 days cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: intravenous on days 1, 8 and 15 of each 28-days cycle at fixed dose of 60 mg/m2, as a 30-60 min i.v. infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bio-specimen Retention
Description: Samples with DNA and without DNA
Study: NCT01544465

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured Physical Activity
Description: Rehabilitation evaluation and 8 weeks of physical therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Physical Activity
Description: Rehabilitation evaluation and 8 weeks of physical therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep hygiene education
Description: Educational materials on insomnia published by the American Academy of Sleep medicine
Study: NCT02658110

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein
Description: 20 g whey protein isolate (Arla Foods Ingredients Group) added to 200ml water and served as a beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein
Description: 20 g whey protein isolate (Arla Foods Ingredients Group) added to 200ml water and served as a beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein
Description: 20 g whey protein isolate (Arla Foods Ingredients Group) added to 200ml water and served as a beverage

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Mixed Macronutrient Breakfast Meal
Description: A standardised mixed-macronutrient breakfast served to all participants. The macronutrient distribution of the breakfast is 13% protein, 70% carbohydrate, 17% fat (1958 kJ; 468 kcal total)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed Macronutrient Breakfast Meal
Description: A standardised mixed-macronutrient breakfast served to all participants. The macronutrient distribution of the breakfast is 13% protein, 70% carbohydrate, 17% fat (1958 kJ; 468 kcal total)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed Macronutrient Breakfast Meal
Description: A standardised mixed-macronutrient breakfast served to all participants. The macronutrient distribution of the breakfast is 13% protein, 70% carbohydrate, 17% fat (1958 kJ; 468 kcal total)
Study: NCT00545493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: tacrolimus capsules, dosing according to blood trough levels: 12-15 ng/ml during months 1-6, 5-10 ng/ml during months 7-12 and 5-8 ng/ml thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: i.v. immunoglobulins
Description: infusions, dosing: initially on three consecutive days 0,4 g/kg KG, thereafter 0,4 g/kg KG every month, after 12 months of treatment every two months).
Study: NCT02508649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selepressin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selepressin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selepressin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selepressin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01036594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: 200mg during first week of study (run-in phase), then 400mg po tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: 200mg during first week of study (run-in phase), then 400mg po tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone 20mg po qam and 10mg po qpm~If participant has ≥30% PSA decline at 12 week evaluation, treatment continues until progressive disease (by RECIST criteria OR by PSAWG criteria) is documented. After that, drug will be discontinued. If participant has \<30% PSA decline, patient goes off study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 0.5mg po bid~If ≥ 30% PSA decline (Prostate-specific antigen) at 12 week evaluation, administration starts when disease progression (by RECIST criteria OR by PSAWG criteria) is documented.
Study: NCT00783939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactic Acid
Description: Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)
Study: NCT01819467

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Seprafilm
Description: Seprafilm will be placed onto the uterine incision and the anterior midline of the uterus following the primary cesarean section
Study: NCT02070367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Somatosensory rehabilitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual treatment: physiotherapy
Study: NCT02658110

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed Macronutrient Breakfast Meal
Description: A standardised mixed-macronutrient breakfast served to all participants. The macronutrient distribution of the breakfast is 13% protein, 70% carbohydrate, 17% fat (1958 kJ; 468 kcal total)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Mixed Macronutrient Lunch Meal
Description: A standardised mixed-macronutrient lunch served to all participants. The macronutrient distribution of the lunch is 14% protein, 51% carbohydrate, 35% fat (3506 kJ; 838 kcal total)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed Macronutrient Lunch Meal
Description: A standardised mixed-macronutrient lunch served to all participants. The macronutrient distribution of the lunch is 14% protein, 51% carbohydrate, 35% fat (3506 kJ; 838 kcal total)
Study: NCT02070367

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual treatment: physiotherapy
Study: NCT02996942

Intervention type: BIOLOGICAL
Intervention: Factor VIII replacement
Description: Patients receive their usual treatment